Donepezil, rivastigmine, galantamine and memantine for ...

160
References
176. Aneshensel CS, Pearlin LI, Levy-Storms L, Schuler
RH. The transition from home to nursing home
mortality among people with dementia. J Gerontol
B Psychol Sci Soc Sci 2000;55:S152–62.
177. Mitchell SL, Kiely DK, Hamel MB, Park PS,
Morris JN, Fries BE. Estimating prognosis for
nursing home residents with advanced dementia.
JAMA 2004;291:2734–40.
178. Clark CM, Sheppard L, Fillenbaum G, Galasko D,
Morris JC, Koss E, et al. Variability in annual minimental
state examination score in patients with
probably Alzheimer’s disease. Arch Neurol 1999;
56:857–62.
179. Neumann PJ, Araki SS, Arcelus A, Longo A,
Papadopoulos G, Kosik KS, et al. Measuring
Alzheimer’s disease progression with transition
probabilities: estimates from CERAD. Neurology
2001;57:957–64.
180. Morris JC, Heyman A, Mohs RC, Hughes JP,
van Belle G, Fillenbaum G, et al. The Consortium
to Establish a Registry for Alzheimer’s Disease
(CERAD). Part I. Clinical and neuropsychological
assessment of Alzheimer’s disease. Neurology 1989;
39:1159–65.
181. Mendiondo MS, Kryscio RJ, Schmitt FA. Models of
progression in AD: predicting disability and costs
[comment]. Neurology 2001;57:943–4.
182. BBC News. Britons ignoring dementia signs. 2004.
183. Wilkinson D, Stave C, Keohane D, Vincenzino O.
The role of general practitioners in the diagnosis
and treatment of Alzheimer’s disease: a
multinational survey. J Int Med Res 2004;32:149–59.
184. Williams A. The measurement and valuation of health.
A chronicle. Discussion Paper 136. York: University
of York Centre for Health Economics; 1995.
185. Kavanagh S, Knapp M. Costs and cognitive
disability: modelling the underlying associations.
Br J Psychiatry 2002;180:120–5.
186. Kavanagh S, Knapp M. Cognitive disability and
direct care costs for elderly people. Br J Psychiatry
1999;174:539–46.
187. Neumann, Hermann RC, Weinstein MC.
Measuring QALYs in dementia. In Wimo A,
Jonsson B, Karlsson G, Winblad B, editors. Health
economics of dementia. Chichester: John Wiley; 1998.
188. McDaid D. Estimating the costs of informal care
for people with Alzheimer’s disease:
methodological and practical challenges. Int J
Geriatr Psychiatry 2001;16:400–5.
189. Department of Health. Prescription cost analysis
2003. URL: http://www.dh.gov.uk/
PublicationsAndStatistics/Publications/
PublicationsStatistics/. Accessed 2004.
190. The European Agency for the Evaluation of
Medicinal Products. Note for guidance on medicinal
products in the treatment of Alzheimer’s disease.
London: CPMP; 1997.
191. Holmes C, Lovestone S. Long-term cognitive and
functional decline in late onset Alzheimer’s
disease: therapeutic implications. Age Ageing 2003;
32:200–4.
192. Wilcock G, Howe I, Coles H, Lilienfeld S,
Truyen L, Zhu Y, et al. A long-term comparison of
galantamine and donepezil in the treatment of
Alzheimer’s disease. Drugs Aging 2003;20:777–89.
193. Jonsson L, Lindgren P, Wimo A, Jonsson B,
Winblad B. Costs of mini mental state
examination-related cognitive impairment.
Pharmacoeconomics 1999;16:409–16.
194. Statistic yearbook. Stockholm: Statistica
Centralbyrån; 1995.
195. Canadian study of health and aging: study
methods and prevalence of dementia. CMAJ 1994;
150:899–913.
196. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA,
Hauck WW, et al. The economic burden of
Alzheimer’s disease care. Health Aff (Millwood)
1993;12:164–76.
197. Ernst RL, Hay JW, Fenn C, Tinklenberg J,
Yesavage JA. Cognitive function and the costs of
Alzheimer disease: an exploratory study. Arch
Neurol 1997;54:687–93.
198. Hux MJ, O’Brien BJ, Iskedjian M, Goeree R,
Gagnon M, Gauthier S. Relation between severity
of Alzheimer’s disease and costs of caring. CMAJ
1998;159:457–65.